Press Releases

Media Contact: Michelle Kirkwood, Director, Strategic Communications and Media Relations, press@diabetes.org

The most recent press releases from the American Diabetes Association:

June 23, 2017
American Diabetes Association Urges Senators to Vote Against Proposed Health Care Legislation
The American Diabetes Association has grave concerns about the impact the draft Senate health care bill will have on people with diabetes. Individuals with diabetes need access to continuous health care to effectively manage their disease and to prevent dangerous and costly complications.

June 13, 2017
SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes
A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for heart failure when used to treat patients with type 2 diabetes, both with or without existing cardiovascular disease, and regardless of the specific SGLT2 inhibitor used, according to a study, “Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD-REAL Study.”

June 13, 2017
Increased Risk of Depression, Anxiety and Disordered Eating for People with Diabetes—Psychosocial Care is Key
Details of a new initiative focused on educating mental health providers on psychosocial care of people with diabetes and the results of two research studies focused on various psychosocial aspects of living with diabetes were highlighted at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 13, 2017
Daily, Long-Acting Oral Insulin Tablet Provides Comparable Glycemic Control to Insulin Glargine Injection in Patients with Type 2 Diabetes
A long-acting, oral insulin tablet has been found to safely improve glycemic control as effectively as the common, injected insulin glargine in people with Type 2 diabetes, according to the study, “Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM).”

June 13, 2017
Glucagon-Blocking Drug Reduces Need for Insulin and Improves Blood Glucose Levels for Patients with Type 1 Diabetes
A single dose of the glucagon-blocking drug REMD-477 can substantially reduce the amount of insulin needed and improve glucose levels without increasing hypoglycemia (low blood glucose levels) in patients with type 1 diabetes, according to the study, “REMD-477, a Human Glucagon Receptor (GCGR) Antibody, Reduces Daily Insulin Requirements and Improves Glycemic Control in People with Type 1 Diabetes (T1D).”

June 12, 2017
New, Long-Acting Insulin Therapy Demonstrates Cardiovascular Safety and Reduces the Risk of Severe Hypoglycemia
A new, ultra-long acting insulin product, insulin degludec, has comparable cardiovascular safety to insulin glargine U100 and is also associated with significant reductions in severe hypoglycemia, investigators presented during a symposium today, titled “Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results,” at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 12, 2017
Health Disparities Among Patients with Diabetes Can Be Improved by New Approaches and Insights
Health disparities in the U.S., including inequalities in the delivery of care and access to care across various racial, ethnic and socioeconomic groups, are of widespread concern, particularly in people with diabetes who require continuous, regular health care to effectively manage their disease.

June 12, 2017
Autoantigen GAD-Vaccine is Safe for Children at High Risk for Developing Type 1 Diabetes
Treatment with autoantigen specific therapies, such as Alum-GAD, is safe to give to children with an increased risk for developing type 1 diabetes, however, it does not prevent the development of the disease, investigators explained in the research study, “A Double-Blind, Randomized Investigator-initiated Study to Determine the Safety and the Effect of Diamyd® on the Progression to Type 1 Diabetes in Children With Multiple Islet Cell Autoantibodies.”

June 12, 2017
Structured Care Program Offers Youth with Type 1 Diabetes Improved Transition from Pediatric to Adult Care
Adolescents and young adults with type 1 diabetes benefit from a structured transition program when changing from pediatric to adult diabetes care, resulting in improvements in clinic attendance and satisfaction, as well as decreased emotional burden for the duration of intervention, according to the study, “A Structured Transition Program in Young Adults with Type 1 Diabetes Is Associated with Improved Satisfaction with Diabetes Care,” presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 12, 2017
Hybrid Closed-Loop System Demonstrates Effectiveness in Controlling Glucose Levels in Children and Adults with Type 1 Diabetes
The performance of closed-loop systems and their ability to prevent hypoglycemia is highlighted in two studies presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 11, 2017
Long-Term Metformin Treatment Found to Reduce Risk of Heart Disease in Adults with Type 1 Diabetes
Metformin may be an effective long-term strategy worthy of adding to an individual’s diabetes care plan in order to reduce the risk of heart disease in adults with type 1 diabetes, according to the findings of the study titled, “Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL),” presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 11, 2017
Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
The medication alirocumab, a PCSK9 inhibitor, reduces LDL cholesterol levels as well as non-high-density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes, according to two ODYSSEY DIABETES (DM) presentations at the “Inhibition of PCSK9 in Dyslipidemia Patients with Diabetes” symposium at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 10, 2017
A Two-Way Text Messaging System Benefits Glycemic Control for Teens with Type 1 Diabetes
Teens with type 1 diabetes (T1D) who adhere to frequent communication through a two-way text messaging system were found to maintain or improve A1C levels while preparing to transition from pediatric to adult care settings, according to the study, “Text Message Intervention for Teens with Type 1 Diabetes (T1D) Preserves A1C: Results of an RCT.”

June 9, 2017
Severe Obesity in High-Risk Youth Correlates Directly to Increased Incidence of Type 2 Diabetes
The risk of developing type 2 diabetes (T2D) by age 20 was 12 times as high in severely obese American Indian children 5 to 9 years of age as in normal-weight youth in that age range, according to a study titled “Long-term Risk of Type 2 Diabetes in Youth with Increasing Severity of Obesity.”

June 9, 2017
Overweight Boys Who Return to Normal Weight Before Young Adulthood Eliminate Increased Risk of Developing Type 2 Diabetes as Adults
Males who are overweight in childhood but achieve normal weight as young adults do not have an increased risk of type 2 diabetes in adulthood, compared to men who were never overweight, according to a study titled “Are Adverse Effects of Child Overweight on Risk of Type 2 Diabetes Reversible by Remission to Normal Weight in Young Adulthood?”

June 5, 2017
Kishwar Azad, MRCS, LRCP, FCPS, MSc, to Receive American Diabetes Association’s 2017 Vivian Fonseca Scholar Award
Kishwar Azad, MRCS, LRCP, FCPS, MSc, FRCPCH (Hon), has been selected to receive the Association's 2017 Vivian Fonseca Scholar Award recognizing diabetes research focused on the South Asian, Asian American, Native Hawaiian and Pacific Islander populations, and/or research by a scientist from these areas in memory of Mr. P. Nagendran.

June 2, 2017
Mark E. Cooper, AO, MB BS, PhD, FRACP, Receives the American Diabetes Association’s 2017 Edwin Bierman Award
Mark E. Cooper, AO, MB BS, PhD, FRACP, has been selected to receive the American Diabetes Association 2017 Edwin Bierman Award, recognizing a leading scientist who has made outstanding contributions in the field of diabetes-related macrovascular complications and related risk factors.

June 1, 2017
Gernot Desoye, PhD, Receives American Diabetes Association’s 2017 Norbert Freinkel Award
Gernot Desoye, PhD, has been selected to receive the American Diabetes Association® (Association) 2017 Norbert Freinkel Award, given in memory of Norbert Freinkel, a dedicated and insightful investigator and a gifted writer. The award honors a researcher who has made outstanding contributions, including scientific publications and presentations, to the understanding and treatment of diabetes in pregnancy.

May 31, 2017
Michael A. Harris, PhD, Named American Diabetes Association’s 2017 Richard R. Rubin Award Recipient
Michael A. Harris, PhD, has been selected to receive the American Diabetes Association's 2017 Richard R. Rubin Award, recognizing a behavioral researcher who has made outstanding, innovative contributions to the study and understanding of the behavioral aspects of diabetes in diverse populations.

May 26, 2017
Dana Dabelea, MD, PhD, Receives American Diabetes Association’s Kelly West Award for Outstanding Achievement in Epidemiology
Dana Dabelea, MD, PhD, is the recipient of the Association's 2017 Kelly West Award for Outstanding Achievement in Epidemiology, recognizing significant contributions to the field of diabetes epidemiology.

  • Last Reviewed: November 18, 2013
  • Last Edited: May 1, 2017